Artelo Biosciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

EQUITY (Detail Narrative)

EQUITY (Detail Narrative)					1 Months Ended			4 Months Ended		12 Months Ended
EQUITY (Detail Narrative)	May 13, 2022	Feb. 15, 2022 shares	Mar. 05, 2021 $ / shares shares	Feb. 12, 2021 $ / shares shares	Jul. 21, 2021 $ / shares shares	Nov. 30, 2020 $ / shares shares	Aug. 17, 2018 shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($)	Dec. 31, 2022 USD ($) integer $ / shares shares	Aug. 31, 2021 USD ($) $ / shares shares	Aug. 31, 2020 USD ($) $ / shares shares	Dec. 29, 2022 shares	Aug. 10, 2022 shares	Jun. 30, 2022 $ / shares shares	Feb. 18, 2022 shares	Sep. 01, 2021 shares
Common stock, par value (in dollars per share) \| $ / shares								$ 0.001		$ 0.001
Common stock, shares authorized								50,000,000		50,000,000	50,000,000			750,000,000
Preferred stock, par value (in dollars per share) \| $ / shares								$ 0.001		$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized								416,667		416,667	416,667	6,250,000		6,250,000
Preferred stock, shares outstanding								0		0	0	0
Preferred stock, shares issued								0		0	0	0
Number of purchase common stock shares \| integer										674,667
Common stock shares issued during period										1,184,959
Common stock, average price per share \| $ / shares										$ 15.90
Proceeds from commission and fees \| $										$ 18,262
Number of shares issued under options							25,000,000
Options exercisable description	Lincoln Park of up to $20,000 worth of the Company’s Common Stock, over the thirty-six (36) month term of the Lincoln Park Agreements. The Company issued to Lincoln Park 19,532 shares of its Common Stock as commitment shares in consideration for entering into the Lincoln Park Agreements and received no funds in exchange for such commitment shares, valued at $97. Upon initiation of the Lincoln Park Agreements, the Company recorded $381 as an expense within general and administrative expenses						Options may be exercisable (“vest”) immediately or in increments based on time and/or performance criteria as determined by the administrator. The term of any option may not exceed 10 years (five years for any incentive stock option granted to a 10% stockholder), and unless otherwise determined by the administrator, each option must terminate no later than three months after the termination of the optionee’s employment (one year in the event of death or disability). Subject to a few minor exceptions, options may not be transferred other than by will or by the laws of descent and distribution.
Number of warrant granted										674,667,000	10,120,000
Intrinsic value of the warrants \| $								$ 0		$ 0	$ 338
Number of shares granted during period												74,000,000
Common stock shares issued for cash \| $									$ 6,578,000	$ 18,262,000		$ 1,978,000
Common stock, shares issued								2,820,068		2,855,688	1,635,109
Valuation [Member]
Options Granted								143,322		4,002	183,680
Option Granted, Value \| $								$ 1,170		$ 18	$ 5,760
Stock option expense \| $								934		2,458	1,497
Stock option expense, Related parties \| $								811		2,216	1,340
Stock option expense, Unamortized \| $								4,489		1,748	4,263
Stock option expense, Unamortized, Related parties \| $								$ 3,717		$ 1,219	$ 3,664
Options Outstanding								333,945		313,109	190,623
Options Outstanding, intrinsic value \| $								$ 0		$ 0	$ 37
2018 Equity Incentive Plan
Exercise price \| $ / shares															$ 4.89
Shares returned to option pool		17,177
Common stock reserved for future issuance										133,334			428,353		4,002	141,003	244,940
Common stock, shares available to be issued										309,417			737,770			6,077
Common stock, shares returned																1,584
Common stock, shares issuable										622,526
2018 Equity Incentive Plan \| Employees Directors And Consultants [Member]
Options granted										52,988
Options granted exercise price \| $ / shares										$ 9.45
Options granted term										ten (10) years
Options issued to non-employees vesting percentage										33.00%
Options issued to non-employees vesting period										24-month
Options issued to employees vesting period										36-month
2018 Equity Incentive Plan \| Principal Executive Officer [Member]
Options granted										90,334
Options granted exercise price \| $ / shares										$ 9.45
Options granted term										ten (10) years
Options issued to non-employees vesting percentage										25.00%
Options issued to non-employees vesting period										24-month
Options issued to employees vesting period										36-month
Options granted in fiscal year 2021 [Member]
Options issued to non-employees vesting percentage			25.00%	50.00%
Exercise price \| $ / shares			$ 22.80	$ 39.90	$ 15.00	$ 9.05
Options granted to purchase shares of common stock			38,340	55,634	4,669
Options Granted						8,000
Options grant description						The Company anticipates the compensation to be $15 to $20 per year for the first year and $20 to $30 for the second year and thereafter, subject to formal approval by the Board.
Options granted in fiscal year 2021 [Member] \| Options 1 [Member]
Options issued to non-employees vesting percentage				50.00%
Exercise price \| $ / shares			$ 22.80	$ 39.90
Options granted to purchase shares of common stock			2,000	47,036
Options granted in fiscal year 2021 [Member] \| Options 2 [Member]
Options issued to non-employees vesting percentage				25.00%
Exercise price \| $ / shares				$ 39.90
Options granted to purchase shares of common stock				28,001
Common Stock [Member]
Common stock, shares issued											1,302,363
Expenses payable \| $										$ 6,579
Common stock , shares issued for exercise of warrants										534,779
Proceeds from exercise of warrants \| $										$ 6,016
Offering costs \| $										$ 96
Common stock, shares issued during period										92,917
Net proceeds \| $										$ 1,524
Average price \| $ / shares										$ 18.00
Commission fee \| $										$ 51
Gross sales price per share of common stock percentage										3.00%